Society, T.A.C. (2014). Understanding what cancer is: Ancient times to present. https://www.cancer.org/cancer/understanding-cancer/history-of-cancer/what-is-cancer.html.

Miller, K.D., Nogueira, L., Devasi, T., Mariotto, A.B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R.L. (2022). Cancer treatment and survivorship statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 409–436.

PubMed  Google Scholar 

Gonzalez-Nicolini, V., & Fussenegger, M. (2005). In vitro assays for anticancer drug discovery—A novel approach based on engineered mammalian cell lines. Anti-Cancer Drugs, 16, 223–228.

Article  CAS  PubMed  Google Scholar 

Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., & Mitchell, J. (1993). Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines. British Journal of Cancer, 68, 1104–1109.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Merlin, J.-L., Barberi-Heyob, M., & Bachmann, N. (2002). In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines. Annals of Oncology, 13, 1743–1748.

Article  PubMed  Google Scholar 

Morse, D. L., Gray, H., Payne, C. M., & Gillies, R. J. (2005). Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Molecular Cancer Therapeutics, 4, 1495–1504.

Article  CAS  PubMed  Google Scholar 

Scherbakov, A. M., Basharina, A. A., Sorokin, D. V., Mikhaevich, E. I., Mizaeva, I. E., Mikhaylova, A. L., Bogush, T. A., & Krasil’nikov, M.A. (2023). Targeting hormone-resistant breast cancer cells with docetaxel: A look inside the resistance. Cancer Drug Resistance, 6, 103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pilco-Ferreto, N., & Calaf, G. M. (2016). Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. International Journal of Oncology, 49, 753–762.

Article  CAS  PubMed  Google Scholar 

Xiong, J., Fan, F., Zhang, Y., Chen, W., & Mao, W. (2016). Epirubicin inhibits proliferation of breast cancer cells through upregulating p21cip1 expression. International Journal of Clinical and Experimental Medicine, 9, 22764–22772.

CAS  Google Scholar 

Barok, M., Tanner, M., Köninki, K., & Isola, J. (2011). Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Research, 13, 1–11.

Article  Google Scholar 

Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., McNulty, A. M., Gong, X., Boehnke, K., & Du, J. (2017). Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget, 8, 69493.

Article  PubMed  PubMed Central  Google Scholar 

Jost, T., Heinzerling, L., Fietkau, R., Hecht, M., & Distel, L. V. (2021). Palbociclib induces senescence in melanoma and breast cancer cells and leads to additive growth arrest in combination with irradiation. Frontiers in Oncology, 11, 740002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marinelli, O., Romagnoli, E., Maggi, F., Nabissi, M., Amantini, C., Morelli, M. B., Santoni, M., Battelli, N., & Santoni, G. (2020). Exploring treatment with ribociclib alone or in sequence/combination with everolimus in ER+ HER2− Rb wild-type and knock-down in breast cancer cell lines. BMC Cancer, 20, 1–13.

Article  Google Scholar 

Yunokawa, M., Koizumi, F., Kitamura, Y., Katanasaka, Y., Okamoto, N., Kodaira, M., Yonemori, K., Shimizu, C., Ando, M., & Masutomi, K. (2012). Efficacy of everolimus, a novel m TOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Science, 103, 1665–1671.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hassan, F., El-Hiti, G. A., Abd-Allateef, M., & Yousif, E. (2017). Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells. Saudi Medical Journal, 38, 359.

Article  PubMed  PubMed Central  Google Scholar 

Mitropoulou, T. N., Tzanakakis, G. N., Kletsas, D., Kalofonos, H. P., & Karamanos, N. K. (2003). Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. International Journal of Cancer, 104, 155–160.

Article  CAS  PubMed  Google Scholar 

Reddel, R. R., Murphy, L. C., Hall, R. E., & Sutherland, R. L. (1985). Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Research, 45, 1525–1531.

CAS  PubMed  Google Scholar 

Villegas, V. E., Rondón-Lagos, M., Annaratone, L., Castellano, I., Grismaldo, A., Sapino, A., & Zaphiropoulos, P. G. (2016). Tamoxifen treatment of breast cancer cells: Impact on Hedgehog/GLI1 signaling. International Journal of Molecular Sciences, 17, 308.

Article  PubMed  PubMed Central  Google Scholar 

Kaminska, K., Akrap, N., Staaf, J., Alves, C. L., Ehinger, A., Ebbesson, A., Hedenfalk, I., Beumers, L., Veerla, S., & Harbst, K. (2021). Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast Cancer Research, 23, 1–18.

Article  Google Scholar 

Kalous, O., Conklin, D., Desai, A. J., O’Brien, N. A., Ginther, C., Anderson, L., Cohen, D. J., Britten, C. D., Taylor, I., & Christensen, J. G. (2012). Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Molecular Cancer Therapeutics, 11, 1978–1987.

Article  CAS  PubMed  Google Scholar 

Li, J., Ma, M., Yang, X., Zhang, M., Luo, J., Zhou, H., Huang, N., Xiao, F., Lai, B., & Lv, W. (2020). Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. Molecular Cancer, 19, 1–18.

Article  PubMed  PubMed Central  Google Scholar 

Oprea-Lager, D. E., Bijnsdorp, I. V., Van Moorselaar, R. J., Van den Eertwegh, A. J., Hoekstra, O. S., & Geldof, A. A. (2013). ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. Anticancer Research, 33, 387–391.

CAS  PubMed  Google Scholar 

Lima, T. S., Iglesias-Gato, D., Souza, L. D., Stenvang, J., Lima, D. S., Røder, M. A., Brasso, K., & Moreira, J. M. (2021). Molecular profiling of docetaxel-resistant prostate cancer cells identifies multiple mechanisms of therapeutic resistance. Cancers, 13, 1290.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haldrup, J., Weiss, S., Schmidt, L., & Sørensen, K. D. (2023). Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening. Scientific Reports, 13, 9043.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan, W., Zhang, Z., Kimball, H., Qu, F., Berlind, K., Stopsack, K. H., Lee, G.-S.M., Choueiri, T. K., & Kantoff, P. W. (2021). Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells. Clinical Cancer Research, 27, 2087–2099.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kakouratos, C., Kalamida, D., Lamprou, I., Xanthopoulou, E., Nanos, C., Giatromanolaki, A., & Koukourakis, M. I. (2021). Apalutamide radio-sensitisation of prostate cancer. British Journal of Cancer, 125, 1377–1387.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holliday, D. L., & Speirs, V. (2011). Choosing the right cell line for breast cancer research. Breast Cancer Research, 13, 215. https://doi.org/10.1186/bcr2889

Article  PubMed  PubMed Central  Google Scholar 

He, S., Zhang, C., Shafi, A. A., Sequeira, M., Acquaviva, J., Friedland, J. C., Sang, J., Smith, D. L., Weigel, N. L., Wada, Y., & Proia, D. A. (2013). Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. International Journal of Oncology, 42, 35–43. https://doi.org/10.3892/ijo.2012.1698

Article  CAS  PubMed  Google Scholar 

Stewart-Miller, H.a.G., Abby (2020). The cell culture innovations increasing drug discovery success. https://www.ddw-online.com/the-cell-culture-innovations-increasing-drug-discovery-success-1600-202008/.

Cree, I. A., Glaysher, S., & Harvey, A. L. (2010). Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Current Opinion in Pharmacology, 10, 375–379.

Article  CAS  PubMed  Google Scholar 

Linnenbringer, E., Gehlert, S., & Geronimus, A. T. (2017). Black-white disparities in breast cancer subtype: The intersection of socially patterned stress and genetic expression. AIMS Public Health, 4, 526.